The results of the first 14 AML patients treated with UniCAR2-T-CD123 were recently reported at the 2022 ASH Meeting showing that: (i) the treatment was generally well tolerated with a limited number of treatment-related adverse events; (ii) 10 patients showed a decrease in blast cell counts, including two CRi, one patient with MRD positive CR converted to level of negativity, and four PR [113] (Table 1). This evidence concerns the gene IL3RA and acute myeloid leukemia.